Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US Food and Drug Administration (FDA) to initiate a Phase I clinical study for HLX42, an antibody drug conjugate (ADC) co-developed with Shanghai Henlius Biotech Inc. (HKG: 2696) and Suzhou-based Medilink Therapeutics. The study targets advanced/metastatic solid tumors.
HLX42, a novel ADC candidate, targets the epidermal growth factor receptor (EGFR) and is conjugated with humanized IgG1 EGFR antibody molecules, novel cleavable ligands, and a TOPO I small molecule payload. Pre-clinical studies indicate that HLX42 inhibits tumor growth with good safety and was approved for Phase I in China last month.- Flcube.com
